
Table 7

Cpd.No. (Ex.No.)	Inhibition of CNV progression
315 (202)	A
323 (203)	A
324 (204)	B
331 (205)	B
333 (207)	A
335 (209)	B
341 (212)	A
348 (215)	B
349 (215)	A
351 (216)	B
387 (234)	B
391 (238)	B
392 (239)	B
397 (244)	B
403 (250)	A
413 (260)	A
414 (261)	B
419 (266)	B
434 (284)	A

CLAIMS


1. A compound of Formula (I):



(I)

or pharmaceutically acceptable salts, racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridyl which is substituted with 1 to 2 R^{38};

M is ;

wherein


* represents the point of attachment to D; and

† represents the point of attachment to Z;

Z is -O-;

Ar is phenyl, optionally substituted with 0 to 4 R^2 groups; and

G is selected from the group consisting of

;

wherein

each R^{38} is -C_0-C_6alkyl-(optionally substituted heterocycle);


R^2 at each occurrence is independently selected from -H and halogen;

each R^{13} is -H,;







Q is cyclopropyl;

.

2. The compound according to claim 1, wherein G is

		.

3. The compound according to claim 1, wherein

D is pyridyl substituted with , , , , , or .

4. The compound according to claim 1, which is selected from the group consisting of 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((2-oxo-1,3-oxazinan-3-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea,
or pharmaceutically acceptable salts, racemic and scalemic mixtures, diastereomers and enantiomers thereof.

5. A composition comprising a compound according to any of claims 1 to 4.

6. An *in vitro* method of inhibiting kinase activity, the method comprising contacting the kinase with a compound according to any of claims 1 to4or a composition thereof.

7. A compound according to any of claims 1 to 4 or a composition thereof for use in (i) a method of inhibiting angiogenesis or (ii) a method of treating a cell proliferative disease.

8. A compound according to any of claims 1 to 4 or a composition thereof for use in a method of treating an ophthalmic disease, condition or disorder.